Evidence map›Paper›PMID 32606640›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2020

Critical Error Frequency and the Impact of Training with Inhalers Commonly used for Maintenance Treatment in Chronic Obstructive Pulmonary Disease.

David J Collier, Pascal Wielders, Job van der Palen, Logan Heyes, Dawn Midwinter, Kathryn Collison, Andy Preece, Neil Barnes, Raj Sharma

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03114969 (An Open-label, Low Interventional Clinical Study Investigating Error Rates), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03114969 completednot on this map

An Open-label, Low Interventional Clinical Study Investigating Error Rates (Critical and Overall) Prior to Any Retraining in Correct Use of the ELLIPTA Dry Powder Inhaler (DPI) Compared to Other DPIs Including; DISKUS, Turbuhaler, HandiHaler and Breezhaler as a Monotherapy or in Combination, in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD)

TypeobservationalSponsorGlaxoSmithKlineRan2017 to 2018Enrolled450ConditionsPulmonary Disease, Chronic ObstructiveArmsRelvar ELLIPTA, Symbicort TURBUHALER, Seretide DISKUS, Spiriva HANDIHALER, BREEZHALER
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Journal of aerosol medicine and pulmonary drug delivery · 2023
    Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

David J CollierWilliam Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0003-0866-4058
Pascal WieldersDepartment of Pulmonary Diseases, Catharina Hospital, Eindhoven, Netherlands.
Job van der PalenDepartment of Pulmonology, Medisch Spectrum Twente, Enschede, Netherlands.ORCID 0000-0003-1071-6769
Logan HeyesRespiratory Therapy Area Unit, GlaxoSmithKline Plc., Stockley Park, Uxbridge, UK.ORCID 0000-0003-4723-8123
Dawn MidwinterRespiratory Therapy Area Unit, GlaxoSmithKline Plc., Stockley Park, Uxbridge, UK.ORCID 0000-0003-2434-1152
Kathryn CollisonRespiratory Medical Franchise, GlaxoSmithKline Plc., Research Triangle Park, Durham, NC, USA.ORCID 0000-0001-6315-0450
Andy PreeceRespiratory Therapy Area Unit, GlaxoSmithKline Plc., Stockley Park, Uxbridge, UK.ORCID 0000-0002-2239-2020
Neil BarnesWilliam Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0001-7981-5197
Raj SharmaRespiratory Therapy Area Unit, GlaxoSmithKline Plc., Stockley Park, Uxbridge, UK.
GlaxoSmithKline (United Kingdom) · GBQueen Mary University of London · GBMedisch Spectrum Twente · NLRadboud University Nijmegen · NLResearch Triangle Park Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Training in correct inhaler use, ideally in person or by video demonstration, can minimize errors but is rarely provided in clinics. This open-label, low-intervention study evaluated critical error rates with dry-powder inhalers (DPIs), before and after training, in patients with chronic obstructive pulmonary disease. Methods: Patients prescribed an inhaled corticosteroid (ICS)/long-acting β Results: The intent-to-treat population comprised 450 patients. At V1, fewer patients made ≥1 critical error with ELLIPTA (10%) versus other ICS/LABA DPIs (Turbuhaler: 40%, OR 4.66, Conclusion: Fewer patients made critical errors with ELLIPTA versus other ICS/LABA, and LAMA or LAMA/LABA DPIs. The effect of "verbal" training highlights its importance for reducing critical errors with common DPIs.

Indexed as

Pulmonary Disease, Chronic ObstructiveAdministration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDry Powder InhalersHumansMuscarinic AntagonistsAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsMuscarinic Antagonistscritical errorsELLIPTAinhaled corticosteroidinhaler techniquelong-acting muscarinic antagonistlong-acting β2-agonist

Identifiers

PMID32606640
PMCPMC7294437
OpenAlexW3033407864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.